Show simple item record

dc.contributor.authorMedlinskiene, Kristina*
dc.contributor.authorFay, M.*
dc.contributor.authorPetty, Duncan R.*
dc.date.accessioned2019-03-05T10:07:21Z
dc.date.available2019-03-05T10:07:21Z
dc.date.issued2019-04
dc.identifier.citationMedlinskiene K, Fay M and Petty D (2019) Uptake of oral anticoagulants for stroke prevention in patients with atrial fibrillation in a single Clinical Commissioning Group in England without restrictions to their use. Clinical Drug Investigation. 39(4): 401-405.en_US
dc.identifier.urihttp://hdl.handle.net/10454/16880
dc.descriptionYesen_US
dc.description.abstractBackground and Objective In England, the uptake of direct oral anticoagulants (DOACs) for stroke prevention in atrial fbrillation has been slow and varied across diferent Clinical Commissioning Groups (CCGs). This study aimed to profle the prescribing of oral anticoagulants for stroke prevention in patients with atrial fbrillation over 3 years in a CCG without restrictions to DOACs use to understand more about organisational and/or individual barriers to the early uptake of DOACs. Methods Data were collected from nine general practices between 1 April 2012 and 31 March 2015 of patients who were initiated on the oral anticoagulant therapy. Data were analysed descriptively and with independent Student’s t test and Chi square test to explore if there was an association between type of oral anticoagulant initiated and sex, age, type of prescriber and prior aspirin use. Results The early uptake of DOACs signifcantly increased over the study period (p<0.0001; medium size efect φc=0.372). There was no statistically signifcant diference between sex or age and type of oral anticoagulant initiated. Primary-care prescribers were responsible for initiating the majority of oral anticoagulants (71%; N=257) and driving the use of DOACs (72%, N=71). Patients switched from aspirin to an oral anticoagulant were more likely to be initiated on warfarin than a DOAC. Conclusions The early use of DOACs, in a CCG without restrictions to their use, was embraced by primary-care prescribers in this particular CCG.en_US
dc.description.sponsorshipBayer Pharmaceuticals via an unrestricted educational grant.en_US
dc.language.isoenen_US
dc.relation.isreferencedbyhttps://doi.org/10.1007/s40261-019-00763-yen_US
dc.rights© Springer Nature Switzerland AG 2019. Reproduced in accordance with the publisher's self-archiving policy. The final publication is available at Springer via https://doi.org/10.1007/s40261-019-00763-yen_US
dc.subjectDirect oral anticoagulants (DOACs)en_US
dc.subjectClinical Commissioning Group (CCG)en_US
dc.subjectStroke preventionen_US
dc.subjectAtrial fibrillationen_US
dc.titleUptake of oral anticoagulants for stroke prevention in patients with atrial fibrillation in a single Clinical Commissioning Group in England without restrictions to their useen_US
dc.status.refereedYesen_US
dc.date.Accepted2019-02-08
dc.date.application2019-02-25
dc.typeArticleen_US
dc.type.versionAccepted manuscripten_US
refterms.dateFOA2019-03-05T10:07:21Z


Item file(s)

Thumbnail
Name:
Medlinskiene_Clinical_Drug_Inv ...
Size:
234.8Kb
Format:
PDF

This item appears in the following Collection(s)

Show simple item record